February 15, 2023

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:

Lauren Hamill Laura Crotty

 

Re:	ZyVersa Therapeutics, Inc.
	Registration Statement on Form S-1, as amended
	File No. 333-269442

 

Ladies and Gentlemen:

 

ZyVersa Therapeutics, Inc. hereby requests that its acceleration request dated February 13, 2023 be withdrawn. Please call Jared Kelly of Lowenstein Sandler LLP at (973) 597-2400 with any questions.

 

	Sincerely,
	ZYVERSA THERAPEUTICS INC.
	By:	/s/ Stephen Glover
	Name:	Stephen Glover
	Title:	Chief Executive Officer